Tricuspid Valve

This channel is dedicated to news and trends in tricuspid valve interventions, surgical and transcatheter, to manage regurgitation and valve stenosis. The tricuspid valve is a rapidly growing area in structural heart interventions. Minimally invasive transcatheter tricuspid valve replacement (TTVR) and repair using transcatheter edge to edge repair (TEER) clips are expected to become a new standard of care in the next couple years, partly because open heart tricuspid surgery has historically has poor outcomes.

Cardiologist shares positive first-in-human data on TriCares TTVR device
The new Topaz TTVR system was associated with the consistent elimination of tricuspid regurgitation. In addition, none of the first 20 patients treated with the device required a permanent pacemaker as a result of the procedure.
No longer the ‘forgotten valve’: Tricuspid valve surgery outcomes keep improving
Patient outcomes after tricuspid valve replacement have improved significantly over the years, according to new data published in The Annals of Thoracic Surgery.
CMS proposes Medicare coverage for T-TEER
CMS has proposed covering tricuspid TEER for patients who present with symptomatic tricuspid regurgitation despite optimal medical therapy. The agency still has questions about the available data, however, and is seeking public comments as it makes its final decision.
First comprehensive T-TEER resource examines best practices for tricuspid valve repair
"We wanted to ensure that every interventionalist, regardless of location or resources, has access to the best information possible," one co-author said.
Key trends in transcatheter tricuspid valve interventions
Steven Bolling, MD, noted that tricuspid treatments have been linked to consistent benefits in terms of quality of life. However, he said, finding clear improvements in clinical outcomes has been more challenging.

K-Clip annuloplasty system for tricuspid regurgitation by Shanghai Huihe Medical Technology Co.

Cardiologists detail world's first use of new annuloplasty system for tricuspid regurgitation

Early data suggest the new transcatheter tricuspid valve repair device could make a big impact on patient care, but additional research is still necessary.

VDyne Valve for transcatheter tricuspid valve replacement

Cardiologists highlight early success of new TTVR system for tricuspid regurgitation

Results from a first-in-human study suggest this new-look device could provide cardiologists and their care teams with another way to treat tricuspid regurgitation in high-risk patients.

TriClip triumphs: Tricuspid edge-to-edge repair linked to strong 30-day outcomes in real-world setting

The new study, published in the Journal of the American College of Cardiology, focused on more than 500 patients treated with Abbott’s TriClip device in Europe.

TricValve Transcatheter Bicaval Valves System and HeartMate II LVAD

Cardiologists shed new light on treating severe tricuspid regurgitation in high-risk heart failure patients

The 80-year-old patient was experiencing severe TR and already had a HeartMate II LVAD.

The LuX-Valve Plus transcatheter tricuspid valve replacement (TTVR) device

Cardiologists make history, perform TTVR with new-look valve for first time in U.S.

The new valve was placed inside the damaged valve via a catheter that is inserted through a small incision in the patient's neck.

Paul Sorajja, MD, director, Center for Valve and Structural Heart Disease, Minneapolis Heart Institute, Abbott Northwestern Hospital, was the principal investigator for the late-breaking TRILUMINATE pivotal trial at the American College of Cardiology (ACC) 2023 meeting and explains details of this landmark trial. #ACC #ACC23 #triluminate

TRILUMINATE trial may pave the way for FDA clearance for tricuspid valve clip device

Paul Sorajja, MD, discusses the late-breaking TRILUMINATE pivotal trial at ACC.23 and how tricuspid TEER performed against the current standard of care using medical therapy.

ACC.23 Together with the World Congress of Cardiology

Day 1 at ACC.23 features late-breaking studies on bempedoic acid, tricuspid valve repair and statins

The conference kicked off with three late-breaking studies that could have a huge impact on patient care going forward.

Edwards Lifesciences Corporation has shared new one-year data on the safety and effectiveness of its Evoque transcatheter tricuspid valve replacement (TTVR) system among patients with tricuspid regurgitation (TR)

Edwards shares new one-year data on transcatheter tricuspid valve replacement

The new findings, presented at the PCR London Valves 2022 conference, focused on mortality and heart failure hospitalization rates.

Tricuspid Valve

Cardiologist shares positive first-in-human data on TriCares TTVR device

No longer the ‘forgotten valve’: Tricuspid valve surgery outcomes keep improving

CMS proposes Medicare coverage for T-TEER

First comprehensive T-TEER resource examines best practices for tricuspid valve repair

Key trends in transcatheter tricuspid valve interventions